Inflammation risks in clonal hematopoiesis and cancer
Official title: Inflammatory Disease Associations in Clonal Hematopoiesis
Funded at Dana-Farber Cancer Inst · NIH-11394516 · Data updated 2026-11-12
This grant studies how clonal hematopoiesis may drive inflammatory diseases and helps predict who is at risk so doctors can prevent complications in people with blood cancers.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $165,240 |
| NIH project number | 5K08HL171883-03 |
| Project ID | NIH-11394516 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with clonal hematopoiesis or CCUS, especially those at risk for inflammatory conditions and/or treated with hypomethylating agents.
✕Less likely to help
Individuals without CH or inflammatory disease history may not directly benefit from this research.
What this research studies
Clonal hematopoiesis is a pre-cancerous expansion of blood cells. The project aims to link CH with inflammatory diseases, develop a reliable risk model, and explore how certain therapies affect inflammation in CH-related conditions. Researchers will analyze patient data to identify CH genotypes associated with inflammatory outcomes and build a statistical tool to estimate individual risk. A subset of patients with CCUS receiving hypomethylating agents will be studied to see how treatment influences inflammatory symptoms. The work could lead to better risk stratification and targeted management for people with CH and related conditions.
Why it matters
Potential benefit: Patients with clonal hematopoiesis could gain risk predictions and tailored strategies to prevent or better manage inflammatory diseases.
How similar studies have gone: Past work has linked CH to cancer and inflammation, but robust clinical risk models for inflammatory outcomes in CH are still emerging.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Weeks, Lachelle Dawn — Dana-Farber Cancer Inst
- Study coordinator: Weeks, Lachelle Dawn
Related research
Other NIH-funded projects on the same topics.
-
Glutathionylated products from lipid oxidation in eye disease
This project studies how lipid-oxidation products in the eye might drive age-related macular degeneration and related conditions, by looking at molecules that behave like inflammatory signals.
-
IgE responses to alpha-gal and how they relate to allergic disease
This project studies why some people develop allergic reactions to mammal products due to alpha-gal and what this means for diagnosing and managing the condition.
-
Alpha‑gal allergy: delayed reactions to red meat and mammal‑derived products
Researchers are looking at why some adults get delayed allergic reactions hours after eating mammal products (alpha‑gal) and how to better diagnose and manage them.
-
A signaling switch that keeps inflammation in check in lupus-like disease
Researchers study how a signaling module in immune cells controls inflammation linked to lupus by examining proteins that turn inflammation on and off.
-
Gut bacteria and steroid hormones in inflammatory bowel disease
A study in people and mice looks at how gut bacteria may change steroids that reduce inflammation in inflammatory bowel disease.
-
Exploring Molecules Linked to Eye Inflammation and Retinal Damage
This project aims to understand how certain molecules, called pseudo leukotrienes, contribute to eye conditions like age-related macular degeneration by studying them in the retina.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.